Investing in the Science of Vitality

Pre-seed through Phase II. In practice that means we often write a first cheque before there is a product, and sometimes before there is a company, then stay through clinical development rather than handing off at Series A.

Science that has reached human proof-of-concept, or a credible path to it. We read the data before the deck: a result, a preprint, a prototype. If the biology is sound we can help with the rest; if it is not, no narrative fixes it.

One email to hello@darkmatter.bio. No warm introduction needed and no screening layer to get past — it is read by a Managing Director. Tell us what you are building in two sentences, where the science stands, who is on the team, your burn rate and your runway.

Both. We lead where we can add operational weight, and we follow where a stronger lead is already in place. We would rather be the useful investor on a cap table than the largest one.

Yes. Our partners have deployed across 16 countries, and a meaningful share of our best deal flow has come from outside the usual hubs. Where you are based matters less to us than what you are building.

Longevity therapeutics, gene therapy, senolytics, NAD+ metabolism, cellular reprogramming and AI drug discovery. Adjacent work in materials, agriculture and consumer science if the underlying biology is the hard part.